Researchers for the Foundation Fighting Blindness (FFB) Clinical Consortium Investigator Group, based in Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan,… Read More »USH2A: self-reported functional vision measured in associated retinal degeneration by the Michigan Retinal Degeneration Questionnaire (MRDQ).
A new real-world study, led by Massachusetts General Hospital, Harvard Medical School, Boston, US, have reported a major adverse event on hydroxychloroquine retinopathy, with an… Read More »Hydroxychloroquine dose and duration of use are associated with the risk of hydroxychloroquine retinopathy in a US study.
A large real-world prospective study on the long-term effectiveness and safety of faricimab and “Port Delivery System with ranibizumab” (PDS), for nAMD or DME, is… Read More »Real-world data on treatment of AMD/DME patients with faricimab and port delivery system with ranibizumab will run to 2027 (“VOYAGER” ).
Clinical researchers based in Oregon Health and Science University (OHSU), Portland and the Ocular Genomics Institute, Mass Eye and Ear, Harvard University, have published the… Read More »CRISPR experimental treatment on a Phase 1/2 study for LCA10 patients report meaningful improvements.
A review from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has reported that “orphan designations” (OD) on inherited retinal… Read More »The EMA Committee for Orphan Medicinal Products (COMP) propose a new approach to Orphan Designations (OD) on inherited retinal degenerations (IRDs).
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) have announced a positive opinion for the granting of a marketing authorisation for… Read More »EMA (European Medicines Agency) approves authorisation of ocular formulation of bevacizumab AMD.
Researchers at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, has reported that an estimate cohort of one-third of inherited retinal dystrophy (IRD) patients had… Read More »A prospective cohort study of IRD patients report the frequency and distributions of ophthalmic surgical procedures at the Wilmer Eye Institute.
Researchers at Newcastle University and Sunderland Eye Infirmary, UK, have reported that, to date, there is “no evidence that complement inhibition with any agent improves… Read More »A systematic review on complement inhibitors suggests no evidence to date from functional endpoints in advanced AMD.
The MACUSTAR consortium, supported by the Innovative Medicines Initiative, has received a further support of funding from industry partners Bayer, Novartis and Roche, agreed to… Read More »The MACUSTAR consortium on AMD has received a further support of funding of €3M and an extension for work until 2027.
Researchers at the Hawaiian Eye and Retina meeting in Maui has reported positive 6-month results for RGX-314, for the treatment of wet AMD, using a… Read More »Phase 2 interim data for RGX-314 treatment for wet AMD reports stable BCVA and CRT at six months.
